Since inhibition of GPC1 activity with an anti-GPC1 mAb has shown promising anti-tumor effect in a GPC1-positive ESCC xenograft model, it is anticipated that GPC1 targeted therapies can be developed for other GPC1-positive solid tumors [29]. This evidence concerns the gene GPC1 and esophageal squamous cell carcinoma.